我觉得这是波士顿年会最好的结果

benben00

牛啊，我看到这个消息激动的差点晕过去

benben00

如果这个不是骗子，那肯定个大牛！！！！只有这2个极端！

StephenW

回复 benben00 的帖子

Benben00,

You are right to be cautious. Please read the following comments from Lei, a good friend of hbvers in America:
你谨慎是对. 请阅读雷，一个在美国hbvers好朋友, 以下意见：

Hi everyone,

There were a few of these studies came out of the same hospital in China at
this year's AASLD, including one oral session on the last day. There are
several red flags because these reported response rates are so much higher
than all previously published data. I was hoping that in closer inspection
the data would hold up, I wish I can support some optimism here, but I'm
sorry to say the information presented were just not up to par. At the oral
presentation researchers in the audience were shaking their heads in
disbelief, because the studies were all over the place with no supporting
evidence. Specifically:

1. The presenters did not provide patient demographics (age, race, gender),
or any inclusion /exclusion criteria  -- for all we know these might be
adults recently infected, not chronic infection from birth.
2. The researchers claimed that the 2-year interferon treatment plus a oral
pill were well tolerated, without presenting any side-effects data. Kind of
hard to believe, especially given the concern Michelle raised about
neuropathy seen in a previous study and the well know side effects of just
one year of interferon. There were also apparently no drop outs, which
really should give one pause.
3. In addition to the 30% HBsAg seroconversion rate, they are also
reporting
96% and 100% virological response, and 70% HBeAg seroconversion rates. This
is totally unheard of, not even remotely close. Numerous studies using
these
exact same treatments have not shown adding an oral drug to interferon does
any good, nor has any study using a longer treatment duration been shown to
improve efficacy. Since these study are not using any new treatment
strategy, and they are done in people with genotype B and C, a group
traditionally with response rates in the mid 10% range, These results are
highly if not totally impossible. Since these studies all came out of the
same hospital, I suspect we are seeing some sort of lab error or patient
selection process.

So, I would say at this point these researchers will need to submit their
data to a peer review medical journal with all supporting data and undergo
a
rigorous review, before these results, however promising, can be accepted.

Lei

benben00

我们是期望有这样的结果的，但是目前看起来太值得怀疑了

hatecccdna

不要盲目乐观，国内出的数据，要审慎的看待。

我查了查，发文的lei是肝炎／艾滋病专家，他／她的意见有道理。

StephenW

回复 hatecccdna 的帖子

雷于2008年加入治疗行动小组的肝炎/艾滋病项目。他与国内和国际活动家，研究人员，制药业的代表，监管机构对新药物开发和治疗病毒性肝炎访问与对病毒肝炎和艾滋病毒合并感染特别是重点。
http://www.treatmentactiongroup.org/bio.aspx?id=324
Lei joined the Treatment Action Group’s Hepatitis/HIV Project in 2008. He works with both domestic and international activists, researchers, pharmaceutical industry representatives, and regulators on new drug development and treatment access for viral hepatitis, with a particular focus on viral hepatitis and HIV coinfection.

富贵数字

这个帖子需要高手分析分析。

大法师

方法不合适，样本不够大，对照组不清晰，典型的中国试论文结构；不可信，
倒是干扰的时间问题，我认为这才是关键，96周，很多拿金牌的战友是坚持两年的，倒是不一定用联合用药的。

探路人

期待中！

大法师

刚看了lei的意见，基本同意，